Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure
novartis.com/news/media-releases/novartis-acquire-regulus-therapeutics-and-farabursen-investigational-microrna-inhibitor-treat-adpkd-most-common-genetic-cause-renal-failure
Regulus is a clinical-stage biopharmaceutical company developing microRNA therapeutics with a focus on autosomal dominant polycystic kidney disease (ADPKD), a severe renal disease
- Lead asset for ADPKD, farabursen, is a novel, next-generation oligonucleotide targeting miR-17 that…
This story appeared on novartis.com, 2025-04-30 19:15:16.892000.